KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Cash & Current Investments: 2009-2024

Historic Cash & Current Investments for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Dec 2024 value amounting to $77.3 million.

  • Rigel Pharmaceuticals' Cash & Current Investments rose 124.41% to $137.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $399.9 million, marking a year-over-year increase of 84.56%. This contributed to the annual value of $77.3 million for FY2024, which is 35.81% up from last year.
  • As of FY2024, Rigel Pharmaceuticals' Cash & Current Investments stood at $77.3 million, which was up 35.81% from $56.9 million recorded in FY2023.
  • In the past 5 years, Rigel Pharmaceuticals' Cash & Current Investments registered a high of $125.0 million during FY2021, and its lowest value of $56.9 million during FY2023.
  • In the last 3 years, Rigel Pharmaceuticals' Cash & Current Investments had a median value of $58.2 million in 2022 and averaged $64.2 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first skyrocketed by 117.99% in 2021, then tumbled by 53.42% in 2022.
  • Rigel Pharmaceuticals' Cash & Current Investments (Yearly) stood at $57.3 million in 2020, then spiked by 117.99% to $125.0 million in 2021, then slumped by 53.42% to $58.2 million in 2022, then decreased by 2.19% to $56.9 million in 2023, then spiked by 35.81% to $77.3 million in 2024.